A clinically derived guinea pig dosing model of cisplatin ototoxicity.

Abstract

The guinea pig is a commonly-used animal model in hearing research, as their audible frequency range is similar to that of humans, and they possess comparatively large cochleae among rodents. Numerous studies have investigated the ototoxic effects of cisplatin in guinea pigs, but these have been mostly limited to single high-dose bolus injections of cisplatin. This method of drug administration is not consistent with human treatment schedules, and therefore lacks translational value to clinical applications. We tested several different cisplatin dosing schedules in guinea pigs based on common research based and clinical regimens, measuring the resulting hearing loss and morbidity (weight loss). We propose a dosing paradigm of once-weekly 4 mg/kg cisplatin injections for three weeks to best mimic clinical treatment schedules. This method resulted in a configuration of hearing loss similar to what is observed in humans along with minimal changes in weight.

• Authors: James K Stanford, Nicholas A Bosworth, Drew S Morgan, Tianwen Chen, Christopher Spankovich
• Journal: Hearing research (Hear Res) Vol. 404 Pg. 108202 (05 2021) ISSN: 1878-5891 [Electronic] Netherlands
• PMID: 33621791 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021. Published by Elsevier B.V.

Chemical References

• Antineoplastic Agents
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (toxicity)
• Cisplatin (toxicity)
• Evoked Potentials, Auditory, Brain Stem (drug effects)
• Guinea Pigs
• Hearing
• Hearing Loss (chemically induced)
• Ototoxicity